期刊
CLINICAL IMMUNOLOGY
卷 238, 期 -, 页码 -出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2022.108992
关键词
Lung adenocarcinoma; Natural killer T-cells; Immunotherapy
类别
资金
- Clinical Research Plan of Shenkang Hospital Development Center (SHDC) [SHDC12018112, SHDC2020CR3002A]
- Shanghai Public Health Clinical Center [KY-GW-2020-53, KYGW201803]
- Na-tional 13th Five-Year Grand Program on Key Infectious Disease Control [2018ZX10302103-003]
- National Key Research and Development Program of China [2016YFC1303402]
- Shanghai Municipal Committee for Health and Family Planning [201740194]
- Shanghai Science and Technology Commission [18411967100]
This study is an ongoing single-arm exploratory clinical trial that used iNKT cells, PD-1+CD8+ T cells, and dendritic cells as treatment for patients. Preliminary results showed manageable tolerance and positive tumor response for this immunotherapy.
We performed a single-arm exploratory clinical trial that is ongoing and registered at ClinicalTrials.gov (NCT03093688). Patients were infused with autologous iNKT cells, PD-1 + CD8+ T cells, and dendritic cells every 3-5 weeks, which was considered 1 cycle. The primary endpoints were safety and objective tumor response. The preliminary results from the first three patients are reported here. The first patient received 16 cycles. Computed tomography (CT) examination revealed a stable disease (SD) response after 4 cycles and progressive disease (PD) response after 11 cycles. For the second patient that received 10 cycles, CT examination revealed an SD response after 4 cycles and a PD response after 9 cycles. For the third patient who was treated with 6 cycles, CT examination revealed an SD response after 4 cycles. The patients suffered from only grade 1-2 adverse events. iNKT cell and PD-1 + CD8+ T cell-based immunotherapy showed a manageable tolerability profile.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据